The U.K.'s healthcare regulatory agency issues an alert for CareFusion’s Alaris insulin pump, following a slew of prior troubles for this product. CareFusion (NYSE:CFN) was the target of a a Medical Device Alert from the U.K.'s Medicines & Healthcare Products Regulatory Agency, adding to the list of recent issues with the Alaris infusion pump. The latest alert warned that the safety alarm on the infusion pump may not detect small air bubbles that pose a risk of embolism if transferred to the patient. The San Diego-based device maker issued a warning for the Alaris system in November of 2012 based on post-market surveillance of the system.
